Unmarketable Parcel Sale Facility
Released
Released
Announcement PDF
11 September 2025
ASX Announcement
UNMARKETABLE PARCEL SALE FACILITY
Paradigm Biopharmaceuticals Limited (ASX:PAR) (PAR or the Company), announced today that it has
established an opt-out unmarketable parcel sale facility (Facility) for shareholders who hold less than
$500 worth of fully paid ordinary shares in the Company (Unmarketable Parcel). The Company has
established the Facility for the following reasons:
•
•
•
To give holders of an unmarketable parcel of Shares (less than A$500) the opportunity to
sell their shareholding, without incurring brokerage of handling costs which, in proportion
to the value of their investment, may otherwise render a transaction of this size
unattractive or uneconomic.
To reduce the expense and administration involved in maintaining shareholders with small
Shareholdings.
Based on the Company’s closing price for Shares (sale price) on Monday 8 September 2025
(Record Date) of $0.275, the Company has approximately 13,532 shareholders of which
approximately 37.2% hold an Unmarketable Parcel, which is a holding of less than 1,819
shares.
In accordance with the Company’s Constitution and ASX Listing Rules, the attached letter and Share
Retention Form will be sent to all shareholders holding an Unmarketable Parcel of shares as at
the Record Date.
Shareholders with an Unmarketable Parcel who wish to retain their shareholding need to give the
Company written notice by returning the Share Retention Form by no later than 5.00pm (AEST) on
Thursday 23 October 2025 or acquire additional shares prior to that time such that their holdings
comprise a marketable parcel, otherwise their shares will be sold by the Company.
Shareholders wishing to take advantage of the Facility and have their shares sold by the Company do
not need to take any action.
A summary of key dates in relation to the Facility are as follows:
Record Date for determining Unmarketable Parcels
5.00pm (AEST), 8 September 2025
Despatch of Letter to holders of Unmarketable Parcels
Thursday 11 September 2025
Closing Date for Receipt of Share Retention Forms
5.00pm (AEST) Thursday 23 October 2025
Estimated Unmarketable Parcels payment date
As soon as practicable after 7 November 2025
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland) Limited
Trinity House, Charleston Road
Ranelagh, Dublin 6
paradigmbiopharma.com | info@paradigmbiopharma.com
Documentation in relation to the Facility will shortly be sent to all shareholders who held an
Unmarketable Parcel of shares on the Record Date.
The Company may modify these dates or suspend or terminate the Facility. Any modification,
suspension or termination will be notified to shareholders by way of a market announcement on ASX.
Important Notes
The Company is not licensed to provide financial product advice. The Company makes no
recommendation as to whether you should participate in the Facility. You are encouraged to seek
advice from your legal, financial, taxation or other professional adviser if you are unsure about what
to do in response to this notice.
The attached Information Sheet provides further information about the Facility. If you have any further
questions about the Facility, please contact Automic’s Information Line on:
Australia: 1300 288 664, Overseas: +61 2 9698 5414 or email to hello@automicgroup.com.au
Yours faithfully
Abby Macnish Niven
CFO & Company Secretary
T:
E:
+61 404 216 467 (Simon White)
investorrelations@paradigmbiopharma.com
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland) Limited
Trinity House, Charleston Road
Ranelagh, Dublin 6
paradigmbiopharma.com | info@paradigmbiopharma.com
11 September 2025
Dear Shareholder
UNMARKETABLE PARCEL SALE FACILITY – DISPOSAL NOTICE
We are writing to advise you that Paradigm Biopharmaceuticals Limited (ASX:PAR) (Company) has established
an unmarketable parcel sale facility (Facility) for shareholders who hold less than $500 in value of fully paid
ordinary shares in the Company (Shares) (Unmarketable Parcel) as at 5.00pm (AEST) on 8 September 2025
(Record Date).
The Company is providing this Facility to assist holders of Unmarketable Parcels who might otherwise find it
difficult to sell their Shares without incurring brokerage or handling costs, due to the size of their holdings.
Holders of Unmarketable Parcels may opt out of the Facility as noted below.
Our registry records show that you held an Unmarketable Parcel of less than 1,819 Shares in the Company,
based on the closing price for Shares on the Record Date of $0.275.
In accordance with clause 10.4(b) of the Company’s constitution (Constitution), if you hold Shares in a CHESS
Holding and they remain in a CHESS Holding after 5.00pm (AEST) on Thursday, 23 October 2025 (Closing Date),
the Company may, without further notice, remove those Shares from the CHESS Holding to an Issuer Sponsored
Holding for the purposes of divestment in accordance with this notice.
The Company will pay all costs of the sale for holders of an Unmarketable Parcel who use this Facility, excluding
tax consequences from the sale which remain the shareholder's responsibility. In accordance with clause
10.4(a) of the Constitution, the Company may sell Shares under the Facility at a price which the Company’s
Directors consider the best price reasonably obtainable for the Shares at the time they are sold. You will receive
this amount, without any deduction for brokerage or handing costs.
As the Company has determined that all payments to shareholders are to be made via direct credit to their
nominated bank account, please ensure your account details are up to date with the Company’s share registry,
Automic Pty Ltd (Automic). You can update your banking and personal details by logging in or registering via
the Automic Investor Portal at: https://investor.automic.com.au/#/home . If you require further assistance,
please contact Automic on Australia: 1300 288 664 Overseas: +61 2 9698 5414.
What do you need to do if you wish to sell your Unmarketable Parcel?
In accordance with clause 10.2(c) of the Constitution, if you wish to sell your Unmarketable Parcel you do not
need to take any action. Your Shares will be sold through the Facility after the Closing Date and the proceeds of
the sale paid to you in accordance with the timetable below.
If you have previously provided the Company with details of an account with an Australian financial institution,
your sale proceeds will be paid in Australian dollars by direct credit into that account. The Company encourages
you to notify it of your account details by completing Step B of Option B of the enclosed Share Sale Election
Form and return it before the Closing Date.
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland) Limited
Trinity House, Charleston Road
Ranelagh, Dublin 6
paradigmbiopharma.com | info@paradigmbiopharma.com
What do you need to do if you wish to retain your Unmarketable Parcel?
In accordance with clause 10.2(b) of the Constitution, should you wish to retain your Shares you must:
(a) complete the attached Share Retention Form and ensure it is received by Automic before the Closing
Date, being 5.00pm (AEST) on Thursday, 23 October 2025; or
(b) alternatively, you may acquire additional Shares so that you hold at least 1,819 Shares as at the Closing
Date. In this event, the Facility will not apply to any of your Shares.
Pursuant to clause 10.2(c) of the Constitution, if the Company has not received a Share Retention Form with
respect to your Shares, or your holding has not increased to at least 1,819 Shares, as at the Closing Date, you
will be deemed to have irrevocably appointed the Company as your agent to sell or otherwise dispose of your
Shares under the Facility and to deal with the proceeds of the sale as contemplated above.
Key Dates
A summary of key dates in relation to the Facility are as follows:
Record Date for determining Unmarketable Parcels
5.00pm (AEST), 8 September 2025
Despatch of Letter to holders of Unmarketable Parcels
Thursday 11 September 2025
Closing Date for Receipt of Share Retention Forms
5.00pm (AEST) Thursday 23 October 2025
Estimated Unmarketable Parcels payment date
As soon as practicable after 7 November 2025
The Company may modify these dates or suspend or terminate the Facility. Any modification, suspension or
termination will be notified to shareholders by way of a market announcement on ASX.
Important Notes
The Company is not licensed to provide financial product advice. The Company makes no recommendation as
to whether you should participate in the Facility. You are encouraged to seek advice from your legal, financial,
taxation or other professional adviser if you are unsure about what to do in response to this notice.
The attached Information Sheet provides further information about the Facility. If you have any further
questions about the Facility, please contact Automic’s Information Line on:
Australia: 1300 288 664, Overseas: +61 2 9698 5414 or email to hello@automicgroup.com.au
Yours faithfully
Abby Macnish Niven
CFO & Company Secretary
T:
E:
+61 404 216 467 (Simon White)
investorrelations@paradigmbiopharma.com
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland) Limited
Trinity House, Charleston Road
Ranelagh, Dublin 6
paradigmbiopharma.com | info@paradigmbiopharma.com
INFORMATION SHEET - UNMARKETABLE PARCEL SALE FACILITY
Why is the Company Implementing the Facility?
The Company welcomes the support of all shareholders, however, the administrative costs in
producing and distributing shareholder communications and maintaining small holdings on the
register through registry fees can be disproportionately high when compared with the dollar value of
small holdings. Additionally, the Facility will assist holders with a small number of Shares who would
find it difficult or expensive to dispose of those Shares through the normal means.
Does the Company have the authority to sell my Shares?
Under ASX Listing Rule 15.13 and clause 10 of the Constitution, the Company has the right to sell
Unmarketable Parcels, unless shareholders give notice to the Company before the Closing Date that
they wish to retain their Shares or acquire additional Shares such that their holding at the Closing Date
comprises a marketable parcel.
What should I do if I wish to sell my Unmarketable Parcel of Shares?
If you wish to sell your Shares without incurring brokerage or handling costs, you can either:
• complete the enclosed Share Sale Election Form, notifying the Company of your election to
sell; or
• alternatively, simply refrain from taking any action.
By refraining from taking any action, you will be deemed to have irrevocably appointed the Company
as your agent:
• to sell all your Shares at a price to be determined by when and how the Shares are sold and
without any cost being incurred by you; and
• to deal with the proceeds of the sale as detailed in this Information Sheet.
If you take no action, your Shares will be sold through the Facility after 23 October 2025 (Closing Date)
and the proceeds (less costs) will be paid to you.
When will my Shares be sold under the Facility?
The sale of Shares under the Facility will occur as soon as practicable after the Closing Date.
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland) Limited
Trinity House, Charleston Road
Ranelagh, Dublin 6
paradigmbiopharma.com | info@paradigmbiopharma.com
Can I purchase more Shares, so my Shares will not be sold?
If you increase your holding so that the number of Shares held is equal to $500, the equivalent of
1,819Shares (i.e., a Marketable Parcel) or more at the Closing Date, then the Company will not sell your
Shares under the Facility.
What if I hold multiple Unmarketable Parcels?
If you hold multiple holdings that, in isolation, are deemed to be Unmarketable Parcels, but when
aggregated would constitute a Marketable Parcel, you can contact Automic to have those holdings
amalgamated into one holding so that this is reflected on the register before the Closing Date. If you
do not do this, each of your holdings will be treated as Unmarketable Parcels.
When and how will I receive sale proceeds?
The proceeds from the sale of your Shares will be remitted to you as soon as practicable after the
completion of the Facility. The expected payment date is as soon as practicable after 7 November
2025 and in any event within eight weeks of the Closing Date. The payment will be made into the
bank account nominated by you to Automic.
If you do not have a bank account nominated with Automic at the time of the payment, the payment
will be held by Automic until bank account details are nominated by you.
Important Notes
This Information Sheet and accompanying letter do not constitute advice, nor a recommendation to
buy, sell or hold Shares in the Company, nor that the Facility is the best way to sell your Shares.
If you are in doubt about what to do, you should consult your legal, financial, taxation or other
professional adviser.
The Company reserves the right to change any of the dates referred to in the accompanying letter, this
Information Sheet or the Share Sale Election Form by written notice to ASX. The Company may, before
a sale of Shares is completed under the Facility, suspend or terminate the Facility, either generally or
in specific cases.
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland) Limited
Trinity House, Charleston Road
Ranelagh, Dublin 6
paradigmbiopharma.com | info@paradigmbiopharma.com
Share your feedback
Discover